The current system for postmarket surveillance of medical devices in the United States is limited. 
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TIMELINE AND SELECTED ACCOMPLISHMENTS
The design, core functions, and overall goals of the TVT Registry have been previously described (1). The program has had a number of key events and accomplishments to date, which are summarized in Registry data, and plans for public reporting. Figure 1 depicts the various stakeholders and primary programmatic output goals of the TVT Registry.
DATA REQUIREMENTS AND SUSTAINED PARTICIPATION
The scope of data collection is a key challenge for the TVT Registry. The initial dataset resulted from collaboration between the professional societies, the FDA, and the CMS, including harmonization with the Valve Academic Research Consortium data elements.
The dataset needed to meet the requirements of multiple stakeholders, including assessment of patient characteristics, procedure indications and results, complications, and longitudinal outcomes. The desire to use the registry for pre-and post-market studies was also considered.
It is difficult to balance data collection sufficient to support the various goals of the TVT Registry stakeholders yet not impose undue burden on sites. Minimizing unnecessary or redundant data collection is a top priority; the TVT Registry has initiated a dedicated effort to reduce the data elements collected. In the future, the increased availability of electronic data (e.g., from electronic health records) may support data capture for programs like the TVT Registry and further reduce, or in some cases obviate, the need for data collection.
In addition, there must be sustained site participation to fulfill the goals of the TVT Registry as a clinical quality program, device surveillance network, and infrastructure for pre-and post-market studies.
The TVT Registry satisfies the requirements of the CMS national coverage determination, which directly supports site participation. Anticipating that the Rumsfeld et al. This process enhances data completeness and accuracy but does not constitute real-time surveillance.
The TVT Registry will need to enhance device surveillance capabilities to optimally support the FDA's strategic plan for device surveillance (8).
POST-APPROVAL STUDIES
It is more challenging to operationalize clinical registries to conduct the formal post-approval studies The hope is to demonstrate efficiencies by using existing registry program sites, contracts, and data collection, augmented by any additional requirements for a specific PAS. Moreover, the TVT Registry data could serve as a de facto PAS by virtue of the capture of virtually all patients receiving a device. In the first year of the TVT Registry, a PAS for the Edwards Sapien valve was successfully designed and approved. Whether clinical registry programs like TVT may be used for a given PAS will be determined by the FDA on a case-by-case basis. The burden is on the TVT Registry to be designed to provide the data that the FDA requires and to ensure that the benefits 
(December)
Launch of the TVT Registry (Version 1).
2011-2012
Professional society collaboration on the development of standards for patient selection and procedural performance to help support anticipated CMS National Coverage Determination, which was released in May 2012.
2011 to present Data are submitted by trained data managers using a web application with data quality checks, following the data quality programs established by STS and NCDR (4) . The data quality program for the STS and NCDR registry programs include training of site data managers, technical support for data submission (e.g., range checks and data quality reporting), data analytics (e.g., missingness and validity of data entries), and auditing. 
2012-2013
Development of PAS and IDE protocols.
2012-2014
Initial presentations and publication of data, including in-hospital outcomes for the initial 7,710 patients in the United States (5). Multiple abstracts were submitted to national meetings in the first 2 years of the registry, including one selected for the Richard E. Clark Award at the 2014 STS Annual Meeting, and another presented as a late-breaking clinical trial at the 2014 ACC Scientific Sessions.
In the first year of the TVT Registry (i.e., through 2012), 156 U.S. centers joined, and 2,400 commercial TAVR records were entered in the registry. As of June 2014, the TVT Registry has 319 participating centers, and there are more than 18,500 TAVR cases in the registry.
(August)
Demonstration of rapid data analytics to help inform a policy recommendation with regard to TAVR alternative access, at the behest of the FDA (6).
2013
Initiation of working groups for TAVR risk models and a mitral procedure module; first TVT risk model (for in-hospital risk-adjusted mortality) completed May 2014, for implementation in the hospital quality benchmark reports.
Joining the International Consortium of Cardiovascular Device Registries to begin global harmonization of medical device registries (7).
2014
Eleven research proposal applications approved for manuscript development, funded by the TVT Registry.
2014 (June) TVT Registry version 2, including reduction of TAVR data elements and modification of some data elements on the basis of site feedback, and addition of the mitral module of the TVT Registry.
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